SCHEMBL24256851

SCHEMBL24256851

CCCc1nc2sc3c(=O)[nH]cnc3c2c2c1CCC2

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.74
POLB P06746 4/20 0.71
KDM4E B2RXH2 6/20 0.65
ALDH1A1 P00352 6/20 0.65
KMT2A Q03164 2/20 0.65
NPSR1 Q6W5P4 5/20 0.62
RXFP1 Q9HBX9 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
HKDC1 Q2TB90 1/20 0.56
OPRK1 P41145 1/20 0.47
MAPK1 P28482 1/20 0.47
RAD52 P43351 1/20 0.47
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
APOBEC3A P31941 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011413 0.86 HPGD (0.57) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL5014751 0.80 HPGD (0.55) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL24256383 0.75 ALDH1A1 (0.59) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL4046040 0.72 HPGD (0.74) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL427971 0.70 ALDH1A1 (0.68) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL24256350 0.70 CHRM4 (0.56) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL4049687 0.69 KDM4E (0.56) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL273173 0.69 CHRM4 (0.57) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL4903113 0.68 IKBKB (0.52) HPGDPOLBKDM4EALDH1A1KMT2A
SCHEMBL4050152 0.68 KDM4E (0.56) HPGDPOLBKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 HPGD 2308/4885POLB 2123/4885KDM4E 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.